drugset / Trial / NCT04645407
Effects of Fuzheng Huayu Tablets on COVID-19
Phase 4
Completed
66 enrolled
ShuGuang Hospital
Hubei Hospital of Traditional Chinese Medicine · collabJingmen No.1 People's Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The 2019 novel coronavirus (2019-nCoV) infection caused clusters of severe respiratory illness similar to SARS and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected 2019-nCoV, most of them should receive supportive care to help relieve symptoms. This clinical trial is to evaluate the effect of Fuzheng Huayu tablet on lung inflammation in intensive patients with novel coronavirus pneumonia and reduce the progressive rate to critical type.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2020-04-15
- Completion
- 2020-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fuzheng Huayu tablet | Unknown | 1.6 g | Oral |